• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

VC-backed startup Bionaut Labs intends to use tiny robots for drug delivery

March 3, 2021 By Brian Buntz

Bionaut LabsEvery once in a while, researchers invoke the 1966 film Fantastic Voyage to describe efforts to use nanotechnology to deliver drugs in the body. A submarine crew shrunk to microscopic size work to damage an injured scientist’s brain in the film.

Now, the company Bionaut Labs (Los Angeles) has emerged from stealth mode to describe its plans to use tiny remote-controlled robots to deliver biologics, nucleic acids and small molecules to targeted regions in the brain. “

“It’s the Fantastic Voyage in real life,” reads a press release announcing the launch of the company, which has won $20 million in funding led by Khosla Ventures.

Bionaut Labs plans to use the funding to test its technology on glioma, a tumor of the nervous system, and explore the potential of its technology for Huntington’s disease, a progressive brain disorder.

The company’s technology could “transform the way the biopharmaceutical industry develops treatments, allowing us to engineer the therapeutic index for improved efficacy and better safety,” said Michael Shpigelmacher, the firm’s CEO, in a statement.

The company can customize the Bionaut technology with precise geometries and surface characteristics to target specific applications. Smaller than one millimeter in size, they can be steered using a magnetic controller to deliver drugs at a precise location.

One barrier that has vexed researchers working to treat brain cancer and other conditions is the blood-brain barrier, which safeguards the brain from foreign materials. “The brain is uniquely designed to protect itself from external factors,” said Dr. Santosh Kesari, director of neuro-oncology at St. John’s Cancer Institute, in a statement. “This makes medical intervention in CNS extremely challenging,’ Kesari added. Kesari is a member of Bionaut Lab’s Advisory Board.

The company has tested its technology in a large-animal in vivo model.

.

 

Filed Under: Drug-Device Combinations, Funding Roundup, Oncology Tagged With: Bionaut Labs, Drug delivery

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS